The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | ctDNA: a promising novel biomarker being explored in lymphoma
In this video, Ash Alizadeh, MD, PhD, Stanford University, Stanford, CA, comments on the value and potential applications of circulating tumor DNA (ctDNA) in lymphoma. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Circulating DNA gives us a non-invasive window into our tumors and their tendency to respond or not respond at various milestones throughout the disease. At diagnosis of the disease tells us what the disease subtype is, what genetic mutations it may have, whether the tumor burden is high or low, through the course of therapy whether that therapy is working or not, and whether at the end of therapy we’ve achieved the goals that we hope to have achieved whether we’ve eradicated the disease using MRD or not...
Circulating DNA gives us a non-invasive window into our tumors and their tendency to respond or not respond at various milestones throughout the disease. At diagnosis of the disease tells us what the disease subtype is, what genetic mutations it may have, whether the tumor burden is high or low, through the course of therapy whether that therapy is working or not, and whether at the end of therapy we’ve achieved the goals that we hope to have achieved whether we’ve eradicated the disease using MRD or not. So those are the various applications and also one other application is to adjudicate radiographic findings when there are equivocal results on an image that we typically need to biopsy, whether we can use that as an alternative.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
